Abstract
Early diagnosis of lung adenocarcinoma requires effective risk predictors. TNFRII was reported to be related to tumorigenesis, but remained unclear in lung cancer. This research set out to investigate the relationship between the sTNFRII (serum TNFRII) level and the risk of lung adenocarcinoma less than 1 cm in diameter. Seventy‐one pairs of subcentimetre lung adenocarcinoma patients and healthy controls were analysed through multiplex bead‐based Luminex assay and found a significantly lower expression of sTNFRII in patients with subcentimetre lung adenocarcinoma than that in the healthy controls (P < .001), which was further verified through ONCOMINE database analysis. Increased levels of sTNFRII reduced the risk of subcentimetre lung adenocarcinoma by 89% (P < .001). Patients with a higher level of BLC had a 2.70‐fold (P < .01) higher risk of subcentimetre adenocarcinoma. Furthermore, a higher BLC/TNFRII ratio was related to a 35‐fold higher risk of subcentimetre adenocarcinoma. TNFRII showed good specificity, sensitivity and accuracy (0.72, 0.75 and 0.73, respectively), with an AUC of 0.73 (P < .001). In conclusion, the present study assessed the value of sTNFRII as a potential biomarker to predict the risk of subcentimetre lung adenocarcinoma and provided evidence for the further use of TNFRII as an auxiliary marker in the diagnosis of subcentimetre lung adenocarcinoma.
Highlights
The latest epidemiological investigation of lung cancer covering 185 countries and 18 million people showed that the incidence and mortality of lung cancer were 11.6% and 18.4%, respectively, both of which were the highest among all malignancies.[1]
This study aimed to analyse the levels of C-reactive protein (CRP), TNFRII and B lymphocyte chemoattractant (BLC) in 71 patients with subcentimetre lung adenocarcinoma and 71 healthy controls to further evaluate the efficacy of sTNFRII in predicting the risk of subcentimetre lung adenocarcinoma
To further assess the potential link, we examined the efficacy of the BLC/TNFRII ratio in predicting the risk of subcentimetre lung adenocarcinoma
Summary
The latest epidemiological investigation of lung cancer covering 185 countries and 18 million people showed that the incidence and mortality of lung cancer were 11.6% and 18.4%, respectively, both of which were the highest among all malignancies.[1]. Recent established inflammatory factors such as IL-8, C-reactive protein (CRP), pentraxin 3 (PTX3) and tumour necrosis factor receptor-2 (TNFRII) have been linked to increased lung cancer risk.[10-13]. Our prior study of 10 widely evaluated inflammatory biomarkers found that elevated levels of B lymphocyte chemoattractant (BLC) increased the risk of subcentimetre lung adenocarcinoma by 2.90-fold.[14]. It has been well-established from a variety of studies that the TNF/TNFR superfamily is correlated with the tumorigenesis and clinical efficacy of multiple tumours, including NSCLC.[11,12,15,16]. This study aimed to analyse the levels of CRP, TNFRII and BLC in 71 patients with subcentimetre lung adenocarcinoma and 71 healthy controls to further evaluate the efficacy of sTNFRII in predicting the risk of subcentimetre lung adenocarcinoma It has been well-established from a variety of studies that the TNF/TNFR superfamily is correlated with the tumorigenesis and clinical efficacy of multiple tumours, including NSCLC.[11,12,15,16] Serum TNFRII is considered to be a hallmark of tumorigenesis because it has been proven to positively regulate cell growth through activating the NF-κB pathway.[17,18] this study aimed to analyse the levels of CRP, TNFRII and BLC in 71 patients with subcentimetre lung adenocarcinoma and 71 healthy controls to further evaluate the efficacy of sTNFRII in predicting the risk of subcentimetre lung adenocarcinoma
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
